HB 1610-FN (2020): establishing the manufacturer pharmaceutical drug take-back program.
Cite this page
Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.
- MLA
- “HB 1610-FN (2020): establishing the manufacturer pharmaceutical drug take-back program.” Granite Record, https://graniterecord.org/bill/2020/hb1610. Accessed 24 Oct. 2026.
- APA
- Granite Record. (n.d.). HB 1610-FN (2020): establishing the manufacturer pharmaceutical drug take-back program. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2020/hb1610
- Chicago
- Granite Record. “HB 1610-FN (2020): establishing the manufacturer pharmaceutical drug take-back program.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2020/hb1610.
- BibTeX
@misc{bill-2020-hb1610, title = {HB 1610-FN (2020): establishing the manufacturer pharmaceutical drug take-back program.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2020/hb1610}, note = {Accessed 24 Oct. 2026} }
HB 1610-FN (2020)
establishing the manufacturer pharmaceutical drug take-back program.
- Status: Referred for interim study
- Term: 2019-2020
- House committee: Health, Human Services and Elderly Affairs
- Subject: Public and Mental Health
The Story
It was introduced on January 8, 2020 and referred to the House Health, Human Services and Elderly Affairs committee. The committee held a public hearing on January 30, 2020. The committee held a work session on February 18, 2020. The committee met in executive session on March 3, 2020 to vote on its recommendation. The committee voted unanimously, 20–0, to recommend that the House study it after the session ends, and the report was placed on the consent calendar. On March 11, 2020 the House voted to study it after the session ends on a voice vote. The committee held a work session on September 3, 2020. The committee reported back on its interim study of the bill: “Not Recommended for Future Legislation”, by a vote of 19 to 0.
Sponsors
- Rep. Tom Loughman (D - Rock 21) (prime sponsor)
- Rep. Gary Merchant (D - Sull 4)
- Rep. Rebecca McBeath (D - Rock 26)
- Rep. Garrett Muscatel (D - Graf 12)
- Rep. Costable (Rock 3)
- Rep. William Fowler (R - Rock 20)
- Sen. Martha Fuller Clark (D - SD21)
- Sen. Tom Sherman (D - SD24)
- Sen. Shannon Chandley (D - SD11)
- Sen. Jeb Bradley (R - SD3)
Hearings and Sessions
- January 30, 2020, 10:45 AM: public hearing, House Health, Human Services and Elderly Affairs, LOB 205
- February 18, 2020, 10:00 AM: subcommittee work session, House Health, Human Services and Elderly Affairs, LOB 205
- March 3, 2020, 10:00 AM: executive session, House Health, Human Services and Elderly Affairs, LOB 205
- September 3, 2020, 2:00 PM: full committee work session, House Health, Human Services and Elderly Affairs
Votes
- March 11, 2020, House: Refer for Interim Study — voice vote, passed
The Docket
- January 8, 2020: Introduced 01/08/2020 and referred to Health, Human Services and Elderly Affairs
- January 30, 2020: Public Hearing: 01/30/2020 10:45 am LOB 205
- February 18, 2020: Subcommittee Work Session: 02/18/2020 10:00 am LOB 205
- March 3, 2020: Executive Session: 03/03/2020 10:00 am LOB 205
- March 11, 2020: Committee Report: Refer for Interim Study for 03/11/2020 (Vote 20-0; CC)
- March 11, 2020: Refer for Interim Study: MA VV 03/11/2020
- September 3, 2020: Full Committee Work Session: 09/03/2020 02:00 pm Members of the public may attend using this link: https://www.zoom.us/j/93480617681 - Executive Session to Follow
- October 6, 2020: Interim Study Report: Not Recommended for Future Legislation (Vote 19-0)